Navigation Links
Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
Date:4/22/2008

STOCKHOLM, April 22 /PRNewswire/ --

- Summary: Using Protein Tomography(TM), Sidec Investigated in Collaboration With Genmab the Molecular Mode of Action of Humax- EGFr (Zalutumumab). In This Study Sidec Showed That EGFr is Flexible and That Zalutumumab Locks the EGFr Into a Very Compact Inactive Conformation Thereby Inhibiting Cell Signaling and Cancer Cell Growth.

Sidec AB announced today that together with Genmab the molecular mode of action of HuMax-EGFr (zalutumumab) has been determined. It was shown that zalutumumab locks the epidermal growth factor receptor (EGFr) molecules into a compact, inactive conformation. Flexibility is crucial to the role of the EGFr in signaling, and this study, done with Sidec's proprietary methodology Protein Tomography(TM), has played a central role in the understanding of the inhibition of individual EGFr molecules. Moreover, Sidec's unique technology confirmed that HuMax-EGFr binds bivalently to the EGFr. Prevention of the receptor dimerization as well as locking the EGFr molecules in the inactive form both contribute to the inhibition of signaling and cancer cell growth.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/294289 )

This data will be demonstrated on Sidec's First Protein Tomography Symposium at the fourth annual PEGS Summit 28 April - 2 May at the Intercontinental Hotel in Boston.

With Protein Tomography it is possible to study the molecular mode of action of individual molecules in situ and in vitro. The unique biological information obtained can also be used to prioritize the most promising monoclonal antibodies/projects and to locate the antibody binding epitope.

"These results clearly show the importance of understanding the molecular mode of action and to capture the flexibility of a receptor when developing therapeutic antibodies. Today this can only be done with Protein Tomography(TM) and we are proud to have contributed to Genmab's new insight to HuMax-EGFr mechanism of action." says Hans Johansson CEO at Sidec AB.

The new findings will be published in the journal Proceedings of the National Academy of Science of the United States of America (PNAS) in the edition published on April 21, 2008

About Sidec

Sidec studies molecular interactions in situ and in vitro using its proprietary technology Protein Tomography(TM). Sidec AB offers collaboration research projects to the biopharmaceutical industry and reveals unique information to prioritize the most promising therapeutic antibody and to locate the antibody binding epitope.

For more information, please contact:

Mr.Hans Johansson, CEO

Phone: +46(0)8-4777-602

http://www.sidec.com


'/>"/>
SOURCE Sidec AB
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
2. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
3. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
4. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
5. Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM)
6. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
7. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
8. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
9. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
10. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
11. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):